AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 253
Study 32675601 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis (ACD and ACDF combined)
Number of subjects: 253
Study 32675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 253
Study 35671100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with ALK Alutard Birch and Grass 1000 SQ‐U, three intralymphatic injections with one-month intervals
Number of subjects: 58
Study 35671100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 35655147 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive and tactile stimulation vest
Number of subjects: 10
Study 32237279 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house general practitioners present in residential aged care facilities
Number of subjects: 15
Study 33979488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg) every 4 weeks for 52 weeks
Number of subjects: 1061
Study 33979488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 33979488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg)
Number of subjects: 1061
Study 33187565 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-kinematic training program using virtual reality, 20 min/week for 4 weeks
Number of subjects: 45
Study 33187565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 34813673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (200 mg/day, median modal dose)
Number of subjects: 1844
Study 34813673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (≥100 mg/day)
Number of subjects: 1844
Study 34813673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 1844
Study 32445670 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous C1‐INH (40 IU/kg or 60 IU/kg) administered twice weekly for 52 to 140 weeks
Number of subjects: 10
Study 36075589 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture in addition to rt-PA intravenous thrombolysis
Number of subjects: 142
Study 36075589 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (rt-PA intravenous thrombolysis only)
Number of subjects: 142
Study 33884661 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem
Number of subjects: 50
Study 33884661 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 50
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Early commencement of parenteral nutrition immediately after birth
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Commencement of parenteral nutrition within 24 hours of admission
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying parenteral nutrition to day 8 of admission
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high doses of amino acids (>3.5 g/kg/day) immediately after birth
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Commencing parenteral nutrition on the first day of life
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition after 72 hours if enteral feeds are not tolerated
Number of subjects: 0
Study 33284201 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding parenteral nutrition within 24 hours of admission
Number of subjects: 0
Study 32502443 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) plus Bevacizumab (15 mg/kg) every 3 weeks
Number of subjects: 223
Study 32502443 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab alone
Number of subjects: 223
Study 35536730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pectoral nerve block (PECS) with 10 ml of 0.5% bupivacaine
Number of subjects: 41
Study 35536730 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guided thoracic paravertebral block (TPV) with 25 ml of 0.25% bupivacaine at T3 level
Number of subjects: 41
Study 33715994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 400 mg BID
Number of subjects: 423
Study 33715994 — intervention group
Group type: COMPARATOR
Intervention: Control (mannitol 50 mg)
Number of subjects: 423
Study 36084912 — intervention group
Group type: COMPARATOR
Intervention: Standard cycling-off setting (expiratory trigger sensitivity set at 25% of peak inspiratory flow)
Number of subjects: 15
Study 36084912 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert optimisation of cycling-off settings
Number of subjects: 15
Study 36084912 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cycling-off settings
Number of subjects: 15
Study 36084912 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert optimisation
Number of subjects: 15
Study 32054899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 85
Study 32054899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33% ropivacaine
Number of subjects: 85
Study 32054899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 85
Study 32054899 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 85
Study 32054899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% and 0.5% ropivacaine
Number of subjects: 85
Study 35553959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for three days
Number of subjects: 44
Study 32899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% + dexmedetomidine 0.5 μg/mL (RD1 group)
Number of subjects: 160
Study 32899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08% + dexmedetomidine 0.5 μg/mL (RD2 group)
Number of subjects: 160
Study 32899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% + sufentanil 0.5 μg/mL (RS1 group)
Number of subjects: 160
Study 32899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08% + sufentanil 0.5 μg/mL (RS2 group)
Number of subjects: 160
Study 32147870 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized syncope decision aid (SynDA)
Number of subjects: 50
Study 32147870 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 32147870 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 33404812 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (109 CFU/day)
Number of subjects: 76
Study 33404812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 32339499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (3 mcg/kg loading dose followed by 16.9 ng/kg/min infusion)
Number of subjects: 0
Study 32339499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32339499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ghrelin receptor blocker (PF-5190457)
Number of subjects: 0
Study 35366660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 149
Study 35366660 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 149
Study 33546069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg 5 minutes after anesthesia induction
Number of subjects: 90
Study 33546069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 90
Study 33546069 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90
Study 33546069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 32048288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soybean meal (FSBM) biscuits
Number of subjects: 0
Study 32048288 — intervention group
Group type: COMPARATOR
Intervention: Soybean meal (SBM) biscuits
Number of subjects: 0
Study 35209924 — intervention group
Group type: EXPERIMENTAL
Intervention: High eGFR group
Number of subjects: 2092
Study 35209924 — intervention group
Group type: COMPARATOR
Intervention: Low eGFR group
Number of subjects: 2092
Study 33473242 — intervention group
Group type: EXPERIMENTAL
Intervention: Commiphora molmol (myrrh) mouthwash used twice a day for 7 days
Number of subjects: 40
Study 33473242 — intervention group
Group type: COMPARATOR
Intervention: Normal saline mouthwash used twice a day for 7 days
Number of subjects: 40
Study 33926138 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Pathology Protocol (LEEPP)
Number of subjects: 168
Study 33926138 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group B)
Number of subjects: 168
Study 32200817 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy of external beam therapy
Number of subjects: 42
Study 32200817 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 42
Study 35450936 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated implementation of clinical practice guidelines (CPG) for 6 months (n=18 wards)
Number of subjects: 10383
Study 35450936 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice guideline dissemination (n=18 wards)
Number of subjects: 10383
Study 32426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education plus lecture-based education
Number of subjects: 101
Study 32426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture-based education
Number of subjects: 101
Study 32426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education
Number of subjects: 101
Study 32426989 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education alone
Number of subjects: 101
Study 32426989 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 101
Study 32787944 — intervention group
Group type: EXPERIMENTAL
Intervention: Training modules for direct care staff on recognition, management, and reporting of R-REM delivered on-site after baseline data collection.
Number of subjects: 1050
Study 32787944 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) in assisted living residences without the intervention.
Number of subjects: 1050
Study 35320163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan technique
Number of subjects: 78
Study 35320163 — intervention group
Group type: COMPARATOR
Intervention: muscle energy technique
Number of subjects: 78
Study 32313941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral flow urine lipoarabinomannan assay (LF‐LAM)
Number of subjects: 1505
Study 32313941 — intervention group
Group type: COMPARATOR
Intervention: Reference standard of positive mycobacterial culture (sputum or urine)
Number of subjects: 1505
Study 33175641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination logistic management training
Number of subjects: 180
Study 33175641 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge and attitude towards management systems
Number of subjects: 180
Study 33175641 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional experience and gender
Number of subjects: 180
Study 32444230 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine mixed with ropivacaine
Number of subjects: 89
Study 32444230 — intervention group
Group type: COMPARATOR
Intervention: Control group (ropivacaine without epinephrine)
Number of subjects: 89
Study 36088783 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice in combination with blood flow restriction training (BFRT)
Number of subjects: 59
Study 36088783 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional high intensity training (HIT)
Number of subjects: 59
Study 36088783 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 59
Study 34143971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 (200 mg every 3 weeks and 15 mg/kg every 3 weeks respectively)
Number of subjects: 595
Study 34143971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305
Number of subjects: 595
Study 34143971 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 595
Study 34143971 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 595
Study 35339706 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted lower trapezius transfer (aLTT)
Number of subjects: 90
Study 35339706 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic-assisted latissimus dorsi transfer (aLDT)
Number of subjects: 90
Study 34170062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 2566
Study 34170062 — intervention group
Group type: COMPARATOR
Intervention: Individualized medical therapy
Number of subjects: 2566
Study 34170062 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2566
Study 35939288 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-CBT-CP
Number of subjects: 278
Study 35939288 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT-CP
Number of subjects: 278
Study 32773515 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 407
Study 32773515 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 407
Study 34345902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with SLE
Number of subjects: 118
Study 34345902 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 118
Study 32196506 — intervention group
Group type: COMPARATOR
Intervention: Single dose of praziquantel (40 mg/kg)
Number of subjects: 153
Study 32196506 — intervention group
Group type: EXPERIMENTAL
Intervention: Four repeated doses of praziquantel (40 mg/kg) administered at two-week intervals
Number of subjects: 153
Study 34693771 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) co-implantation
Number of subjects: 37
Study 34693771 — intervention group
Group type: COMPARATOR
Intervention: No capsular tension ring (CTR) co-implantation (Control)
Number of subjects: 37
Study 32906032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate (MMF)
Number of subjects: 142
Study 32906032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 142
Study 32906032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 35209934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) capsules taken orally on day 1, day 7, and day 14
Number of subjects: 120
Study 35209934 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules taken orally on day 1, day 7, and day 14
Number of subjects: 120
Study 35209934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) capsules
Number of subjects: 120
Study 35209934 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 120
Study 32917259 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation for 48 hours with settings starting at pre-existing PEEP, tidal volume of 6 ml/kg lean body mass, and respiratory rate to maintain arterial pH above 7.2.
Number of subjects: 20
Study 32917259 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation adjusted by the attending ICU team according to lung-protective ventilation strategy.
Number of subjects: 20
Study 35032379 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% and Bupivacaine 0.25% (max 2mg/kg)
Number of subjects: 63
Study 35032379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and Bupivacaine 0.25% with 25 μg of Epinephrine
Number of subjects: 63
Study 35032379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and Bupivacaine 0.25% with 2mg Dexamethasone
Number of subjects: 63
Study 34787868 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy (10 sessions, 90 min each, twice a week)
Number of subjects: 40
Study 34787868 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (Control group)
Number of subjects: 40
Study 35366664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pentazocine
Number of subjects: 142
Study 35366664 — intervention group
Group type: COMPARATOR
Intervention: Alternating doses of pentazocine and acetaminophen
Number of subjects: 142
Study 32385598 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated teaching cues in VR training (experimental group)
Number of subjects: 30
Study 32385598 — intervention group
Group type: COMPARATOR
Intervention: Self-learning without automated teaching (control group)
Number of subjects: 30
Study 33994021 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐learning assignment on breaking bad news (BBN)
Number of subjects: 160
Study 33994021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no E‐learning assignment)
Number of subjects: 160
Study 34339654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus a bevacizumab biosimilar (IBI305)
Number of subjects: 0
Study 34339654 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 35007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrient formula containing omega‐3‐fatty acids, arginine, dietary nucleotides, and soluble fiber (n = 55)
Number of subjects: 110
Study 35007812 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control (n = 55)
Number of subjects: 110
Study 33525480 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐green stalks (NGS)
Number of subjects: 300
Study 33525480 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolored stalks (MS)
Number of subjects: 300
Study 33525480 — intervention group
Group type: COMPARATOR
Intervention: Green stalks (GS)
Number of subjects: 300
Study 33525480 — intervention group
Group type: COMPARATOR
Intervention: Green leaves (GL)
Number of subjects: 300
Study 33525480 — intervention group
Group type: COMPARATOR
Intervention: Multicolored leaves (ML)
Number of subjects: 300
Study 32719274 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy (ART)
Number of subjects: 60
Study 32719274 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensity-modulated radiotherapy (IMRT)
Number of subjects: 60
Study 34535238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperangulated video laryngoscopy (HAVL)
Number of subjects: 15
Study 34535238 — intervention group
Group type: COMPARATOR
Intervention: Standard geometry video laryngoscopy (SGVL)
Number of subjects: 15
Study 32535566 — intervention group
Group type: EXPERIMENTAL
Intervention: CITO-STOP
Number of subjects: 55
Study 32535566 — intervention group
Group type: COMPARATOR
Intervention: Standard hygienic technique
Number of subjects: 55
Study 33902293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach flower remedies (BFR) - 30% hydro-brandy solution with two drops each of Impatiens, White Chestnut, Cherry Plum, Chicory, Crab Apple, and Pine, orally ingested (4 drops, 4 times a day for 4 weeks)
Number of subjects: 81
Study 33902293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach flower remedies (BFR)
Number of subjects: 81
Study 33902293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 33595680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific treatment not detailed)
Number of subjects: 42
Study 33595680 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific treatment not detailed)
Number of subjects: 42
Study 32248846 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal eating (until 'could not eat another bite')
Number of subjects: 14
Study 32248846 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum eating (until 'comfortably full')
Number of subjects: 14
Study 35820629 — intervention group
Group type: EXPERIMENTAL
Intervention: KL130008 (1–20 mg single doses or 2–6 mg multiple doses once daily for seven days)
Number of subjects: 79
Study 35820629 — intervention group
Group type: EXPERIMENTAL
Intervention: KL130008
Number of subjects: 79
Study 35820629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 34548526 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually calculated loading regimen (weekly capsules)
Number of subjects: 52
Study 34548526 — intervention group
Group type: COMPARATOR
Intervention: Monthly drinking solution (24,000 IU vitamin D)
Number of subjects: 52
Study 34548526 — intervention group
Group type: COMPARATOR
Intervention: Monthly capsules (24,000 IU vitamin D)
Number of subjects: 52
Study 35785880 — intervention group
Group type: EXPERIMENTAL
Intervention: Full face mask
Number of subjects: 60
Study 35785880 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 60
Study 32389453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration 1 ng/mL
Number of subjects: 73
Study 32389453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration 2 ng/mL
Number of subjects: 73
Study 32389453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration 3 ng/mL
Number of subjects: 73
Study 32389453 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 32540878 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip tracking
Number of subjects: 26
Study 32540878 — intervention group
Group type: COMPARATOR
Intervention: No needle tip tracking (control)
Number of subjects: 26
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge about cataract
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (≥40 years)
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary school completed
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: High school & above
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmental and non-governmental employed
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Merchant
Number of subjects: 599
Study 33568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Attitude
Number of subjects: 599
Study 33568076 — intervention group
Group type: COMPARATOR
Intervention: Rural residence
Number of subjects: 599